Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

BIZARRE: 2 - What They Never Told You

Druckenmiller's Viking Trade Just Hit A Golden Cross — And A Sweet 36% Gain

Stanley Druckenmiller's Viking Therapeutics Inc (NASDAQ:VKTX) bet is starting to look like a classic Druckenmiller move — quietly bold, impeccably timed, and now technically validated. The billionaire investor's family office took a fresh position in VKTX during the second quarter, buying roughly 549,000 shares at an average price of $25.33.…

Benzinga

Novo, Pfizer Are Battling To Buy The Future Of Weight-Loss — But Viking Already Owns It

Pfizer Inc's (NYSE:PFE) lawsuit. Novo Nordisk A/S' (NYSE:NVO) counterbid. And in the middle of it all — a quiet $45 million position that might turn into Andreas Halvorsen's next masterstroke. After years of fighting from the sidelines of the Ozempic boom, Pfizer is finally throwing punches.

Benzinga

Viking Therapeutics: High Risk, High Reward Play

Viking Therapeutics stock surges as Phase 3 trials progress for its GLP-1 obesity drug, with analysts seeing major upside potential

MarketBeat

From analysis to the latest developments in health,
read the most diverse news in one place.

J.J. McCarthy’s Development and Where the QB Stands With the Vikings

Minnesota’s expectation is that the extra rest it has given the former No. 1 pick will have him prepared to start against the Lions in Week 9.

Sports Illustrated

Why Is Viking Therapeutics Stock Rising Today?

Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX) are rising Thursday. The clinical-stage biopharmaceutical company reported third-quarter earnings and provided updates on clinical trials.

Benzinga

Costa launches first-ever pod coffee machine – but you may struggle to get one

The Podio X1 is here

Viking welcomes two new river cruise ships as fleet approaches 100

The cruise line continues to grow its fleet to boost choice for passengers

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

Martha Stewart just replaced her 27-year-old fridge with a brand new model – it's a luxurious vision of sleekness and durability

Martha Stewart has revealed that her new fridge is a 36-inch bottom freezer refrigerator from Viking, a brand known for its contemporary design and longevity

Homes & Gardens

The Five Best Cruise Lines for Retirees

Retirement is an ideal time for cruising. Check out the five best cruise lines for comfort, ease and unforgettable experiences.

Kiplinger

Viking unveils new Mekong river cruise ship

Passengers can travel through Vietnam from Hanoi to Ho Chi Minh City or vice versa

The Independent UK

Biotech Breakouts: 3 Stocks With Massive Upside Potential

Biotech stocks are highly volatile; however, these biotech stocks have key trial results this fall that could spark sharp moves and long-term growth potential

MarketBeat

What to take to university – and what to leave behind, according to students

Starting university? From extension cables and desk lamps to earplugs and storage boxes, these are the essentials students say they couldn’t live without

The Guardian - UK

Adam Thielen Made Financial Sacrifice in Effort to Rejoin Vikings in Trade

Adam Thielen is taking a pay cut to return to the Minnesota Vikings after two seasons with the Carolina Panthers.

Sports Illustrated

Libyan coastguard shot at migrant rescue ship in Mediterranean, NGO claims

The non-profit SOS Mediterranee says the MV Ocean Viking was targeted while carrying 87 rescued migrants to safety.

Euronews

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

Is Viking’s Growth Still Worth the Premium?

Viking stock dipped after earnings despite strong bookings and raised guidance, as investors focus on slowing pricing growth for 2026

Benzinga

Viking's Premium Valuation Backed By Strong Growth, Analyst Notes

Viking Holdings Ltd (NYSE:VIK) shares slipped on Wednesday despite the cruise operator posting a strong second-quarter revenue jump and upbeat analyst commentary.

Benzinga

Viking's 42% Plunge Splits Experts—A '$129 Strong Buy' Or 'Clearly Inferior' Drug?

Viking Therapeutics Inc. (NASDAQ:VKTX) saw its stock collapse by over 42% on Tuesday after data from its Phase 2 obesity pill trial disappointed investors, sparking a fierce debate between Wall Street bulls and critical biotech experts.

International Business Times UK

Market Bloodbath: Viking Therapeutics Stock Tanks After Obesity Pill Side Effects Trigger Mass Dropouts

Viking Therapeutics shares plunged 40% after trial data for its obesity pill, VK2735, revealed high dropout rates due to side effects, raising doubts about its competitiveness against rivals Eli Lilly and Novo Nordisk.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Viking Obesity Pill Faces Steep Climb Against Lilly's Tirzepatide, Analyst Calls Downtrend Reaction 'Extreme'

Investors appear disappointed with Viking Therapeutics Inc.’s (NASDAQ:VKTX) data from its Phase 2 trial of an obesity pill.

Benzinga

Like Eli Lilly, Viking Therapeutics' Oral Weight Loss Drug Disappoints, Stock Tanks

On Tuesday, Viking Therapeutics Inc. (NASDAQ:VKTX) released the much-awaited data from its Phase 2 trial of VK2735 pill, the company’s dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors.

Benzinga

Top Wall Street Forecasters Revamp Viking Holdings Expectations Ahead Of Q2 Earnings

Viking Holdings Ltd (NYSE:VIK) will release earnings results for the second quarter, before the opening bell on Tuesday, Aug. 19.

Benzinga

Eli Lilly Considering Viking Therapeutics Acquisition? Expert Says 'They're Setting Up For Something BIG' As LLY Issues 40-Year Bond

Eli Lilly And Co.‘s (NYSE:LLY) recent, and highly unusual, issuance of a 40-year bond is fueling speculation that the pharmaceutical giant may be preparing for a major acquisition, with Viking Therapeutics Inc. (NASDAQ:VKTX) emerging as a potential target.

Benzinga

Viking's Oral Obesity Drug Poised To Gain Ground After Eli Lilly's Orforglipron Setback: Analyst

Viking Therapeutics, Inc. (NASDAQ:VKTX) is pressing ahead in the weight-loss drug race with the launch of its Phase 2 VENTURE-Oral trial to test a daily pill version of VK2735 in obese and overweight adults, a move analysts say could position the company to capitalize on Eli Lilly’s recent setback and…

The Independent UK

A first look at Viking Mira, the cruise brand’s new £377m ocean ship

Viking Mira is getting ready to welcome cruise passengers from spring 2026

Barchart

2 Growth Stocks Wall Street Predicts Will Soar 74% to 159%

With a strong pipeline, these two biotechs are poised for explosive growth.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.